Nov 07, 2024 / 01:15PM GMT
Presentation (London-Based Investors)
Nov 07, 2024 / 01:15PM GMT
=====================
Corporate Participants
=====================
* Karsten Munk Knudsen
Novo Nordisk A/S - Chief Financial Officer, Executive Vice President
* Camilla Sylvest
Novo Nordisk A/S - Executive Vice President - Commercial Strategy and Corporate Affairs
* Martin Lange
Novo Nordisk A/S - Executive Vice President - Development
* Jacob Martin Rode
Novo Nordisk A/S - Investor Relations
=====================
Conference Call Participants
=====================
* Sachin Jain
Bank of America - Analyst
* Emily Field
Barclays - Analyst
* Richard Vosser
JPMorgan - Analyst
* Richard Parkes
BNP Paribas Exane - Analyst
* James Quigley
Goldman Sachs - Analyst
* Rajesh Kumar
HSBC - Analyst
* Simon Baker
Redburn Atlantic - Analyst
* Kerry Holford
Berenberg - Analyst
* Emmanuel Papadakis
Deutsche Bank - Analyst
Novo Nordisk AS
(XTER:NOV)
€
43.13
+0.26 (+0.61%)
Market Cap: 190.29 Bil
Enterprise Value: 206.94 Bil
PE Ratio: 11.75
PB Ratio: 7.04
GF Score: 65/100 Q3 2024 Novo Nordisk A/S Earnings Presentation (London-Based Investors) Transcript
Nov 07, 2024 / 01:15PM GMT
Release Date Price:
€98.76
(-1.77%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot